Highlights
Market Capitalization | 1.9K |
Book Value | - $6.53 |
Earnings Per Share (EPS) | -8.88 |
Wall Street Target Price | 30.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -73.24% |
Return On Equity TTM | -615.23% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -19.2M |
Diluted Eps TTM | -8.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | -1.97 |
EPS Estimate Next Quarter | -1.22 |
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Regeneron Pharmaceuticals, Inc. | 0.53% | 20.61% | 40.93% | 82.08% | 313.49% |
 Novo Nordisk A/s | 2.31% | 2.37% | 41.89% | 174.22% | 452.16% |
 Alnylam Pharmaceuticals, Inc. | -2.2% | 76.34% | 35.57% | 40.87% | 212.74% |
 Vertex Pharmaceuticals Incorporated | 2.37% | 15.84% | 38.0% | 150.97% | 173.61% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | 30.21 | 30.21 | 1.55 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 45.38 | 45.38 | 2.06 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | Buy | $125.3B | 313.49% | 30.21 | 32.04% |
Novo Nordisk A/s | Buy | $576.2B | 452.16% | 45.38 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $33.6B | 212.74% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $123.5B | 173.61% | 32.84 | -4.74% |
Insights on ELOX
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 41.9% return, outperforming this stock by 141.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 174.2% return, outperforming this stock by 274.2%
